CRDF (Cardiff Oncology) Moat Score: 2/10 (As of Jun. 29, 2026)


CRDF Cardiff Oncology Inc CRDF
53 GF Score
Price $1.28
GF Value $1.48
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Moat Score?

Cardiff Oncology CRDF +1.60% 53 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates CRDF with a GF Score™ of 53/100 and a GF Value™ of $1.48 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,401 Biotechnology companies, Cardiff Oncology ranks better than 58.1% on this metric.

Cardiff Oncology has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cardiff Oncology has No Moat: Cardiff Oncology Inc lacks significant market leadership and customer loyalty. The company operates in a highly competitive biotech sector with limited intellectual property and no significant cost advantages or regulatory barriers. Its innovation and R&D capabilities are not yet proven to provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cardiff Oncology might have No Moat - Very weak/transient advantages.

Cardiff Oncology  (NAS:CRDF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cardiff Oncology Moat Score Related Terms

CRDF vs MAIA, TELO, OSTX: Moat Score Comparison

For the Biotechnology subindustry, Cardiff Oncology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Moat Score distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Moat Score falls into.


CRDF
53GF Score
Cardiff Oncology Inc CRDF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cardiff Oncology (CRDF) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cardiff Oncology ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Cardiff Oncology's Moat Score too high?
Cardiff Oncology's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Cardiff Oncology's value of 2 is 0% at this industry median. Based on the distribution chart, Cardiff Oncology ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Moat Score compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #587 out of 1401 companies for Moat Score. This puts Cardiff Oncology in the upper half of its industry. The industry median Moat Score is 2.00. Cardiff Oncology's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.28 — trading 13.5% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.28 is trading 13.5% below its estimated GF Value™ of $1.48. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

  • Moat Score: 2
  • GF Value™: $1.48 vs. price of $1.28 (13.5% below fair value)
  • GF Score™: 53/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#587 of 1401)

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
53GF Score

Get the complete analysis for CRDF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price
$1.48
GF Value